logo

Proqr Therapeutics (PRQR)



Trade PRQR now with
  Date
  Headline
10/29/2018 7:35:11 AM ProQR Therapeutics Announces Signing Of Agreement With Ionis Pharma To License QR-1123
9/7/2018 4:27:29 AM ProQR Prices Underwritten Public Offering Of 5.75 Mln Ordinary Shares At $15.75/shr
9/5/2018 4:04:24 PM ProQR Announces Proposed Underwritten Public Offering Of Ordinary Shares
9/5/2018 4:13:32 AM ProQR Announces Positive Interim Results From Phase 1/2 Clinical Trial Of QR-110 In LCA10 Patients
8/15/2018 7:05:08 AM ProQR To Issue Data From Planned Interim Analysis In Ongoing Phase 1/2 Clinical Trial Of QR-110
6/28/2018 7:02:10 AM ProQR Initiates Phase 1/2 Clinical Trial Of QR-313 For Dystrophic Epidermolysis Bullosa
5/9/2018 7:23:12 AM ProQR Therapeutics N.V. Q1 Net Loss €10.7 Mln Or €0.34/shr Vs. Net Loss €10.5 Mln Or €0.45/shr Last Year
4/10/2018 7:04:01 AM ProQR Appoints Peter Beal To Scientific Advisory Board To Focus On Axiomer RNA A-to-I Editing Technology
2/28/2018 7:18:49 AM ProQR Therapeutics Q4 Net Loss EUR 11.3 Mln Or EUR 0.39/Shr Vs Loss EUR 8.8 Mln Or EUR 0.38/Shr Last Year
1/8/2018 7:20:40 AM ProQR And Galapagos Announce Research Collaboration On Fibrosis Targets Using ProQR’s Axiomer® Technology
10/15/2014 12:34:54 PM Deutsche Bank Initiates ProQR Therapeutics (PRQR) At Buy With $32 Price Target